China conditionally approves Hutchmed’s Tazverik for follicular lymphoma

NMPA has granted conditional approval for Hutchmed’s Tazverik to treat adults with relapsed or refractory (R/R) follicular lymphoma (FL)

Mar 23, 2025 - 06:00

China conditionally approves Hutchmed’s Tazverik for follicular lymphoma

NMPA has granted conditional approval for Hutchmed’s Tazverik to treat adults with relapsed or refractory (R/R) follicular lymphoma (FL)

Read the original article

Tags:

Previous Article

New Device Facilitates Direct Communication Between Multiple Quantum Processors

European agencies catch up with speedier regulatory pathways for CGTs in the US

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

STAT+: He’s 19 months old and has one of the world’s rarest diseases. His parents are determined to find a cure.

STAT+: He’s 19 months old and has one of the world’s ra...

Mar 4, 2024

Viatris gets grant for nasal spray method for treating ...

Apr 25, 2024

Bacterial Conjunctivitis drugs in development, 2023

Nov 30, 2023